Organon (NYSE: OGN) GC gets 183,639 RSUs, now holds 92.6K shares

Rhea-AI Filing Summary

Organon & Co. general counsel Kirke Weaver reported compensation-related equity activity. On March 31, 2026, Weaver received a grant of 183,639 Restricted Stock Units (RSUs), each representing a contingent right to one share of Organon common stock. These RSUs vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

On the same date, previously granted RSUs vested and were exercised into 18,513 shares of common stock. To cover tax obligations, 5,275 shares were withheld at a price based on the March 30, 2026 closing market price of $5.70 per share. After these transactions, Weaver directly owned 92,639.163 shares of Organon common stock.

Insider Trade Summary

18,513 shares exercised/converted

Mixed 7 txns

Insider Weaver Kirke

Role Gen. Counsel & Corp. Secy.

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	183,639	$0.00	--
Exercise	Restricted Stock Units	6,201	$0.00	--
Exercise	Restricted Stock Units	12,312	$0.00	--
Exercise	Common Stock	6,201	$0.00	--
Tax Withholding	Common Stock	1,767	$5.70	$10K
Exercise	Common Stock	12,312	$0.00	--
Tax Withholding	Common Stock	3,508	$5.70	$20K

Holdings After Transaction: Restricted Stock Units — 183,639 shares (Direct); Common Stock — 85,602.163 shares (Direct)

Footnotes (1)

1. The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Each RSU represents a contingent right to receive one share of Organon common stock. On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Key Figures

New RSU grant: 183,639 RSUs RSU vesting schedule: 3 equal installments RSUs exercised: 18,513 RSUs +5 more

8 metrics

New RSU grant 183,639 RSUs Granted March 31, 2026 to general counsel

RSU vesting schedule 3 equal installments Vesting on March 31, 2027, 2028, and 2029

RSUs exercised 18,513 RSUs Converted into common stock on March 31, 2026

Tax-withheld shares 5,275 shares Withheld to cover tax obligations on March 31, 2026

Tax valuation price $5.70 per share Closing market price on March 30, 2026 used for RSU grant plan

Post-transaction holdings 92,639.163 shares Organon common stock directly owned after transactions

2023 RSU grant 18,600 RSUs Granted March 31, 2023; remaining one-third vested March 31, 2026

2025 RSU grant 36,937 RSUs Granted March 31, 2025; one-third vested March 31, 2026

Key Terms

Restricted Stock Units, contingent right, tax-withholding disposition, exercise or conversion of derivative security, +1 more

5 terms

Restricted Stock Units financial

"On March 31, 2026, the Reporting Person was granted 183,639 RSUs"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each RSU represents a contingent right to receive one share"

tax-withholding disposition financial

"Payment of exercise price or tax liability by delivering securities"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

exercise or conversion of derivative security financial

"Exercise or conversion of derivative security"

closing market price financial

"The price is the closing market price of Organon & Co. common stock"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weaver Kirke

(Last) (First) (Middle)

C/O ORGANON & CO.

30 HUDSON STREET, FLOOR 33

(Street)

JERSEY CITY NEW JERSEY 07302

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Gen. Counsel & Corp. Secy.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		M		6,201	A	$0	85,602.163	D
Common Stock	03/31/2026		F		1,767	D	$5.7(1)	83,835.163	D
Common Stock	03/31/2026		M		12,312	A	$0	96,147.163	D
Common Stock	03/31/2026		F		3,508	D	$5.7(1)	92,639.163	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/31/2026		A		183,639		(2)	(2)	Common Stock	183,639	$0	183,639	D
Restricted Stock Units	(3)	03/31/2026		M			6,201	(4)	(4)	Common Stock	6,201	$0	0	D
Restricted Stock Units	(3)	03/31/2026		M			12,312	(5)	(5)	Common Stock	12,312	$0	24,625	D

Explanation of Responses:

1. The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted.

2. On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

3. Each RSU represents a contingent right to receive one share of Organon common stock.

4. On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026.

5. On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Remarks:

	/s/ Tarnetta V. Jones, as Attorney-in-Fact for Kirke Weaver	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity award did Organon (OGN) general counsel Kirke Weaver receive?

Kirke Weaver received a grant of 183,639 Restricted Stock Units (RSUs) on March 31, 2026. Each RSU represents a contingent right to receive one share of Organon common stock, increasing his potential future ownership as the units vest over time.

How will Kirke Weaver's 183,639 RSUs from Organon (OGN) vest?

The 183,639 RSUs will vest in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. As each tranche vests, Weaver becomes entitled to receive the corresponding number of Organon common shares.

Did Kirke Weaver sell any Organon (OGN) shares in the market in this Form 4?

The filing shows no open-market sales. Instead, 5,275 shares of common stock were disposed of through tax-withholding transactions, where shares valued at $5.70 each were delivered to cover tax obligations tied to RSU vesting and exercises.

How many Organon (OGN) shares does Kirke Weaver own after these transactions?

After the reported transactions, Kirke Weaver directly owned 92,639.163 shares of Organon common stock. This reflects RSU exercises into shares and shares withheld for taxes, as disclosed in the post-transaction ownership figures within the Form 4.

What earlier RSU grants to Kirke Weaver are referenced in this Organon (OGN) filing?

The filing notes RSU grants of 18,600 units on March 31, 2023 and 36,937 units on March 31, 2025. Portions of these earlier grants vested on March 31, 2026, contributing to the RSU exercises and resulting common stock reported.